Department of Radiation Oncology, University of Lübeck, Germany.
Strahlenther Onkol. 2010 Jun;186(6):307-14. doi: 10.1007/s00066-010-2131-4. Epub 2010 Apr 26.
The prognostic value of the tumor expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 (FLT1) is still unclear. This study investigated the impact of tumor expression of VEGF and FLT1 on outcomes in 61 patients irradiated for stage II/III non-small cell lung cancer (NSCLC).
The impact of tumor VEGF and FLT expression and twelve additional potential prognostic factors on locoregional control (LC), metastases-free survival (MFS), and overall survival (OS) were retrospectively evaluated. These factors included age, gender, performance status, histology, histological grade, T-category, N-category, surgery, chemotherapy, pack-years, smoking during radiotherapy, and hemoglobin levels during radiotherapy.
On univariate analysis, improved LC was associated with lower T-category (p = 0.046), lower N-category (p = 0.047), and not smoking during radiotherapy (p = 0.012). VEGF (p = 0.26) and FLT1 expression (p = 0.70) had no significant impact. On multivariate analysis, lower N-category (p = 0.037) maintained significance; not smoking during radiotherapy was almost significant (p = 0.052). On univariate analysis, improved MFS was associated with lower T-category (p = 0.034) and lower N-category (p = 0.027), and almost with hemoglobin >or= 12 g/dl during radiotherapy (p = 0.053). VEGF (p = 0.80) and FLT1 expression (p = 0.61) had no significant impact. On multivariate analysis, lower N-category (p = 0.040) maintained significance. On univariate analysis, improved OS was associated with lower T-category (p = 0.028), lower N-category (p = 0.003), not smoking during radiotherapy (p = 0.047), and hemoglobin levels >or= 12 g/dl during radiotherapy (p = 0.019). VEGF (p = 0.59) and FLT1 expression (p = 0.85) had no significant impact. On multivariate analysis, lower N-category (p = 0.011) maintained significance.
Tumor expression of VEGF and FLT1 appear to have no significant impact on LC, MFS, or OS in patients irradiated for NSCLC.
血管内皮生长因子（VEGF）和 VEGF 受体 1（FLT1）在肿瘤中的表达的预后价值仍不清楚。本研究调查了 61 例接受 II/III 期非小细胞肺癌（NSCLC）放疗的患者中肿瘤 VEGF 和 FLT1 表达对结局的影响。
回顾性评估肿瘤 VEGF 和 FLT 表达以及 12 个其他潜在预后因素对局部区域控制（LC）、无转移生存（MFS）和总生存（OS）的影响。这些因素包括年龄、性别、表现状态、组织学、组织学分级、T 分期、N 分期、手术、化疗、吸烟包年数、放疗期间吸烟以及放疗期间的血红蛋白水平。
单因素分析显示，LC 改善与较低的 T 分期（p = 0.046）、较低的 N 分期（p = 0.047）和放疗期间不吸烟（p = 0.012）相关。VEGF（p = 0.26）和 FLT1 表达（p = 0.70）无显著影响。多因素分析中，较低的 N 分期（p = 0.037）仍具有显著性；放疗期间不吸烟具有显著意义（p = 0.052）。单因素分析显示，MFS 改善与较低的 T 分期（p = 0.034）和较低的 N 分期（p = 0.027）相关，且与放疗期间血红蛋白水平≥12g/dl 相关（p = 0.053）。VEGF（p = 0.80）和 FLT1 表达（p = 0.61）无显著影响。多因素分析中，较低的 N 分期（p = 0.040）仍具有显著性。单因素分析显示，OS 改善与较低的 T 分期（p = 0.028）、较低的 N 分期（p = 0.003）、放疗期间不吸烟（p = 0.047）和放疗期间血红蛋白水平≥12g/dl 相关（p = 0.019）。VEGF（p = 0.59）和 FLT1 表达（p = 0.85）无显著影响。多因素分析中，较低的 N 分期（p = 0.011）仍具有显著性。
在接受 NSCLC 放疗的患者中，肿瘤 VEGF 和 FLT1 的表达似乎对 LC、MFS 或 OS 无显著影响。
